TRVI
Trevi Therapeutics Inc

1,785
Mkt Cap
$1.42B
Volume
1.65M
52W High
$12.30
52W Low
$2.36
PE Ratio
-29.73
TRVI Fundamentals
Price
$10.65
Prev Close
$11.04
Open
$11.27
50D MA
$10.06
Beta
0.68
Avg. Volume
1.59M
EPS (Annual)
-$0.4698
P/B
7.46
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at D. Boral Capital
D. Boral Capital reissued a "buy" rating and set a $19.00 target price on shares of Trevi Therapeutics in a research note on Friday...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Strong Earnings
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up on Earnings Beat...
MarketBeat·5d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Posts Earnings Results, Beats Expectations By $0.02 EPS
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) issued its earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of...
MarketBeat·6d ago
News Placeholder
Leerink Partners Begins Coverage on Trevi Therapeutics (NASDAQ:TRVI)
Leerink Partners started coverage on Trevi Therapeutics in a research note on Thursday. They issued an "outperform" rating and a $13.00 price target on the stock...
MarketBeat·6d ago
News Placeholder
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates PR Newswire...
PR Newswire·7d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Reaches New 1-Year High - Still a Buy?
Trevi Therapeutics (NASDAQ:TRVI) Sets New 12-Month High - Here's What Happened...
MarketBeat·9d ago
News Placeholder
Y Intercept Hong Kong Ltd Takes $475,000 Position in Trevi Therapeutics, Inc. $TRVI
Y Intercept Hong Kong Ltd acquired a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities...
MarketBeat·12d ago
News Placeholder
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a...
PR Newswire·14d ago
News Placeholder
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference PR Newswire NEW HAVEN, Conn., Nov. 4, 2025 Fireside Chat...
PR Newswire·16d ago
News Placeholder
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·4mo ago

Latest TRVI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.